Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis-Reference-Cited by-同舟云学术

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

Published:2018-02 Issue:2 Volume:6 Page:105-113
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Bethel M Angelyn,Patel Rishi A,Merrill Peter,Lokhnygina Yuliya,Buse John B,Mentz Robert J,Pagidipati Neha J,Chan Juliana C,Gustavson Stephanie M,Iqbal Nayyar,Maggioni Aldo P,Öhman Peter,Poulter Neil R,Ramachandran Ambady,Zinman Bernard,Hernandez Adrian F,Holman Rury R

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference15 articles.

1. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016

2. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Circulation,2017

3. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome;Pfeffer;N Engl J Med,2015

4. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016

5. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Marso;N Engl J Med,2016

Cited by 470 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac alterations induced by Heloderma horridum horridum venom in rats: An experimental study with ECG analysis using a linear regression algorithm;Toxicon;2024-10

2. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence;Current Pharmaceutical Design;2024-08

3. Unveiling the Potential Role of Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review;Cureus;2024-07-31

4. National trends in utilisation of glucose lowering medicines by older people with diabetes in long-term care facilities;Diabetes Research and Clinical Practice;2024-06

5. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials;American Journal of Preventive Cardiology;2024-06